Oct 9 (Reuters) - GNI Group Ltd
* GNI Group announces clearance of investigational new drug (IND) by FDA for F351 clinical trials in the treatment of liver fibrosis
* GNI Group ltd does not expect submission will impact financial results for year ending December 31, 2017
* GNI USA intends to initiate necessary procedures to start a phase I open label study in U.S. in early 2018
* Preliminary results are expected within 2018 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.